BioSpace News Archive

Transparency Market Research has published a new report titled, “Metastatic Bone Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The demand within the global metal implants and medical alloys market is rising on account of advancements in the field of invasive surgery.

Demand for various products in the endoscopy ultrasound market has been on the back of extensive application in gastroenterology over the past several years, noted analysts at Transparency Market Research.

The needles that are used during aspiration and biopsy procedure have been gaining traction in the recent years. The market is competitive with the presence of many market players; each of them jostling with each other to expand the presence in the global aspiration and biopsy needles market.

Vicore Pharma Holding AB announces that the U.S. Food and Drug Administration has accepted the Investigational New Drug application for the company’s lead asset, the orally available angiotensin II type 2 receptor agonist C21, for the treatment of COVID-19.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, reported a full analysis of updated data, including patient-reported outcome measures, from its global Phase 3 ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase deficiency.

X4 Pharmaceuticals, Inc. announced positive preliminary efficacy and safety data from its ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, in Waldenström’s macroglobulinemia patients with both MYD88 and CXCR4 mutations.

Sierra Oncology, Inc. announced data presented at the European Hematology Association Annual Meeting highlighting transfusion independence with momelotinib is associated with improved overall survival, including in patients with anemia at baseline.

Global Blood Therapeutics, Inc. announced new data from the Phase 2a HOPE-KIDS 1 Study that showed children with sickle cell disease ages 4 to 11 years treated with Oxbryta® tablets experienced significant improvements in hemoglobin levels.

Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response